Stay Informed Key dates to watch in 2026: TRIUMPH-1 and TRIUMPH-2 results (mid-2026), head-to-head retatrutide vs tirzepatide results (December 2026), and any NDA filing announcements from Eli Lilly
2.3%) and there was no difference in the percentage of participants with acute pancreatitis or malignant neoplasms between the two groups [110]
Compared to regular sugar, allulose led to a significant reduction in blood sugar levels while providing sweetness
Schedule Your SKINVIVE Consultation Today
Beyond that, some other potential risks included sleep issues, low blood pressure (sometimes leading to fainting), kidney stones, arthritis, and acute pancreatitis
Acta Pharm Sin B 2022;12:2443-61.ArticlePubMedPMC 116